All In Biotech

Drug Trial Radar · NCT06577259

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

A Phase 1, Open-label, Single-site, Randomized, Single-dose, Three-way, Crossover Study to Assess the Relative Bioavailability of BMS-986435 Tablet Formulations in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Sep 3, 2024

Primary completion

Feb 19, 2025

Study completion Feb 19, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the relative bioavailability of BMS-986435 tablet formulations in healthy adult male and female participants.

Conditions

  • Healthy Participants

Interventions

  • BMS-986435Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 105 days
  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]Time frame: Up to 105 days
  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]Time frame: Up to 105 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.